Professional Summary
Education & Certifications
- Residency: University of Iowa Hospitals and Clinics (2005) IA
- Medical Education: Perelman School of Medicine University of Pennsylvania (2004) PA
- Board Certification: United Council for Neurologic Subspecialties, Neuro-Oncology (2015)
-
- Residency: University of California School of Medicine (2009) CA
- Internship: University of California School of Medicine (2007) CA
- Fellowship: Stanford University (2011) CA
- Board Certification: American Board of Psychiatry and Neurology, Neurology (2010)
Honors & Awards
- Selected Participant, NINDs Clinical Trials Training Course (2011)
- Who's Who in America, Marquis (2015)
-
Memberships
- Member, American Society of Clinical Oncology (2010 - Present)
- Member, Society of Neuro-Oncology (2010 - Present)
- Member, American Academy of Neurology (2005 - Present)
-
Publications
-
Management of patients with Schwan nomatosis: Report of six cases and review of the literature
Huang, J. H., Simon, S. L., Nagpal, S., Nelson, P. T., & Zager, E. L. (2004). Management of patients with Schwan nomatosis: Report of six cases and review of the literature. SURGICAL NEUROLOGY, 62(4), 353–361. -
Vasospasm as the sole cause of cerebral ischemia: how strong is the evidence?
Stein, S. C., Levine, J. M., Nagpal, S., & LeRoux, P. D. (2006). Vasospasm as the sole cause of cerebral ischemia: how strong is the evidence? Neurosurgical Focus, 21(3), E2-? -
Decompressive laparotomy to treat intractable cerebral hypoxia.
Nagpal, S., Halpern, C. H., Sims, C., Calland, J. F., Gracias, V. H., Schuster, J. M., … Levine, J. M. (2009). Decompressive laparotomy to treat intractable cerebral hypoxia. Journal of Trauma, 67(5), E152–5. -
-
Treatment and Prevention of Secondary CNS Lymphoma
Nagpal, S., Glantz, M. J., & Recht, L. (2010). Treatment and Prevention of Secondary CNS Lymphoma. SEMINARS IN NEUROLOGY, 30(3), 263–272. -
Cardiac Rupture After Intravenous t-PA Administration in Acute Ischemic Stroke
Dhand, A., Nakagawa, K., Nagpal, S., Gelfand, J. M., Kim, A. S., Smith, W. S., & Tihan, T. (2010). Cardiac Rupture After Intravenous t-PA Administration in Acute Ischemic Stroke. NEUROCRITICAL CARE, 13(2), 261–262. -
Treatment and Prophylaxis of Hematologic Malignancy in the Central Nervous System
Nagpal, S., & Recht, L. (2011). Treatment and Prophylaxis of Hematologic Malignancy in the Central Nervous System. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 13(4), 400–412. -
Bevacizumab improves quality of life in patients with recurrent glioblastoma.
Nagpal, S., Harsh, G., & Recht, L. (2011). Bevacizumab improves quality of life in patients with recurrent glioblastoma. Chemotherapy Research and Practice, 2011, 602812-? -
Polymer Wafers (Gliadel) in the Treatment of Malignant Glioma
Nagpal, S. (2012). Polymer Wafers (Gliadel) in the Treatment of Malignant Glioma. NEUROSURGERY CLINICS OF NORTH AMERICA, 23(2), 289-? -
Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge
Nagpal, S., Riess, J., & Wakelee, H. (2012). Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 13(4), 491–504. -
Neoplastic Myelopathy
Nagpal, S., & Clarke, J. L. (2012). Neoplastic Myelopathy. SEMINARS IN NEUROLOGY, 32(2), 137–45. -
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.
Thomas, R. P., Recht, L., & Nagpal, S. (2013). Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clinical Pharmacology : Advances and Applications, 5, 1–9. -
A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Journal of Thoracic Oncology , 8(2), e17–8. -
The incidence and significance of multiple lesions in glioblastoma
Thomas, R. P., Xu, L. W., Lober, R. M., Li, G., & Nagpal, S. (2013). The incidence and significance of multiple lesions in glioblastoma. JOURNAL OF NEURO-ONCOLOGY, 112(1), 91–97. -
Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI.
Schmiedeskamp, H., Andre, J. B., Straka, M., Christen, T., Nagpal, S., Recht, L., … Bammer, R. (2013). Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI. Journal of Cerebral Blood Flow and Metabolism , 33(5), 732–43. -
A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
Riess, J. W., Nagpal, S., Neal, J. W., & Wake, H. A. (2013). A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(4), 389–94. -
ETIRINOTECAN PEGOL DNA Topoisomerase 1 Inhibitor Oncolytic
Nagpal, S., & Recht, L. D. (2013). ETIRINOTECAN PEGOL DNA Topoisomerase 1 Inhibitor Oncolytic. DRUGS OF THE FUTURE, 38(4), 227–233. -
Risk of Leptomeningeal Disease in Patients Treated With Stereotactic Radiosurgery Targeting the Postoperative Resection Cavity for Brain Metastases
Atalar, B., Modlin, L. A., Choi, C. Y. H., Adler, J. R., Gibbs, I. C., Chang, S. D., … Soltys, S. G. (2013). Risk of Leptomeningeal Disease in Patients Treated With Stereotactic Radiosurgery Targeting the Postoperative Resection Cavity for Brain Metastases. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(4), 713–718. -
Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., … Wakelee, H. A. (2014). Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clinical Lung Cancer, 15(3), 202–6. -
A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. JOURNAL OF THORACIC ONCOLOGY, 8(2), E17–E18. -
Brain Tumor Mutations Detected in Cerebral Spinal Fluid
Pan, W., Gu, W., Nagpal, S., Gephart, M. H., & Quake, S. R. (2015). Brain Tumor Mutations Detected in Cerebral Spinal Fluid. CLINICAL CHEMISTRY, 61(3), 514–22. -
Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
Nagpal, S., Recht, C. K., Bertrand, S., Thomas, R. P., Ajlan, A., Pena, J., … Recht, L. D. (2015). Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. JOURNAL OF NEURO-ONCOLOGY, 123(2), 277–82. -
Glioblastoma Multiforme Recurrence: An Exploratory Study of F-18 FPPRGD(2) PET/CT1
Iagaru, A., Mosci, C., Mittra, E., Zaharchuk, G., Fischbein, N., Harsh, G., … Gambhir, S. S. (2015). Glioblastoma Multiforme Recurrence: An Exploratory Study of F-18 FPPRGD(2) PET/CT1. RADIOLOGY, 277(2), 497–506. -
Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.
Andre, J. B., Nagpal, S., Hippe, D. S., Ravanpay, A. C., Schmiedeskamp, H., Bammer, R., … Zaharchuk, G. (2015). Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain. The Neuroradiology Journal, 28(2), 112–19. -
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58. -
EGFR mutation status and brain metastases in non-small cell lung cancer: an understudied problem
Riess, J. W., & Nagpal, S. (2013). EGFR mutation status and brain metastases in non-small cell lung cancer: an understudied problem. TRANSLATIONAL CANCER RESEARCH, 2(1), 54–56. -
The "Liquid Biopsy": the Role of Circulating DNA and RNA in Central Nervous System Tumors.
Connolly, I. D., Li, Y., Gephart, M. H., & Nagpal, S. (2016). The "Liquid Biopsy": the Role of Circulating DNA and RNA in Central Nervous System Tumors. Current Neurology and Neuroscience Reports, 16(3), 25-? -
Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases
Li, Y., Pan, W., Connolly, I. D., Reddy, S., Nagpal, S., Quake, S., & Gephart, M. H. (2016). Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. JOURNAL OF NEURO-ONCOLOGY, 128(1), 93–100. -
Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
Corbin, Z. A., Nguyen-Lin, A., Li, S., Rahbar, Z., Tavallaee, M., Vogel, H., … Nagpal, S. (2017). Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. Journal of Neuro-Oncology. -
A Phase I/II Trial of 5 Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma Multiforme.
Azoulay, M., Ho, C. K., Fujimoto, D. K., Modlin, L. A., Gibbs, I. C., Hancock, S. L., … Soltys, S. G. (2016). A Phase I/II Trial of 5 Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma Multiforme. International Journal of Radiation Oncology, Biology, Physics, 96(2S), E131–E132. -
PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology.
Neal, J. W., Wakelee, H., Padda, S. K., Bertrand, S., Acevedo, B., Holmes Tisch, A., … Nagpal, S. (2016). PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S271–S272. -
History and current state of immunotherapy in glioma and brain metastasis
McGranahan, T., Li, G., & Nagpal, S. (2017). History and current state of immunotherapy in glioma and brain metastasis. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 9(5), 347–68. -
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Pollom, E. L., Fujimoto, D., Wynne, J., Seiger, K., Modlin, L. A., Jacobs, L. R., … Soltys, S. G. (2017). Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. International Journal of Radiation Oncology, Biology, Physics, 98(1), 123–30. -
Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma.
Shah, J. L., Li, G., Shaffer, J. L., Azoulay, M. I., Gibbs, I. C., Nagpal, S., & Soltys, S. G. (2017). Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma. Neurosurgery. -
AN OVERVIEW OF DNA TOPOISOMERASE I INHIBITORS UNDER DEVELOPMENT
Connolly, I. D., Hixson, J. D., & Nagpal, S. (2016). AN OVERVIEW OF DNA TOPOISOMERASE I INHIBITORS UNDER DEVELOPMENT. DRUGS OF THE FUTURE, 41(12), 731–40. -
A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.
McGranahan, T., & Nagpal, S. (2017). A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer. Current Treatment Options in Oncology, 18(4), 22-? -
First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800.
Miller, S. E., Tummers, W. S., Teraphongphom, N., van den Berg, N. S., Hasan, A., Ertsey, R. D., … Rosenthal, E. L. (2018). First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. Journal of Neuro-Oncology. -
Conditional Probability of Survival as a Proposed Endpoint for Future Single-Arm Clinical Trials in Glioblastoma
Patel, C. B., Thomas, R. P., Nagpal, S., & Recht, L. D. (2017). Conditional Probability of Survival as a Proposed Endpoint for Future Single-Arm Clinical Trials in Glioblastoma. ANNALS OF NEUROLOGY, 82, S206–S207. -
Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
Li, Y., Liu, B., Connolly, I. D., Kakusa, B. W., Pan, W., Nagpal, S., … Hayden Gephart, M. (2018). Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2018). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. The Oncologist. -
A Diffuse Leptomeningeal Glioneuronal Tumor Without Diffuse Leptomeningeal Involvement: Detailed Molecular and Clinical Characterization
Kung, J. H., Buckley, A. F., Nagpal, S., Fischbein, N., & Peters, K. B. (2018). A Diffuse Leptomeningeal Glioneuronal Tumor Without Diffuse Leptomeningeal Involvement: Detailed Molecular and Clinical Characterization. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 77(9), 751–56. -
Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival
Moghavem, N., Wakelee, H. A., & Nagpal, S. (2018). Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival. ANNALS OF TRANSLATIONAL MEDICINE, 6. -
Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.
Albakr, A., Alhothali, W., Samghabadi, P., Maeda, L., Nagpal, S., & Ajlan, A. (2018). Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review. Cureus, 10(11), e3660. -
Current State of Immunotherapy for Treatment of Glioblastoma.
McGranahan, T., Therkelsen, K. E., Ahmad, S., & Nagpal, S. (2019). Current State of Immunotherapy for Treatment of Glioblastoma. Current Treatment Options in Oncology, 20(3), 24. -
Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
Koenig, J. L., Shi, S., Sborov, K., Gensheimer, M. F., Li, G., Nagpal, S., … Pollom, E. L. (2019). Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases. World Neurosurgery. -
Optimizing bevacizumab dosing in glioblastoma: less is more.
Ajlan, A., Thomas, P., Albakr, A., Nagpal, S., & Recht, L. (2017). Optimizing bevacizumab dosing in glioblastoma: less is more. Journal of Neuro-Oncology, 135(1), 99–105. -
Developing a standardized process for oral chemotherapy management for neuro-oncology.
McGranahan, T., Gershon, M., Pena, J., Bains, C., Van Meter, M. E. M. C., Salas, S., & Nagpal, S. (2018). Developing a standardized process for oral chemotherapy management for neuro-oncology. JOURNAL OF CLINICAL ONCOLOGY, 36(30). -
BPM 31510, a clinical stage metabolic modulator, demonstrates therapeutic efficacy in glioblastoma models of temozolomide chemosensitive and resistance by targeting mitochondrial function
Dadali, T., Kulkarni, S., Ng, R., Awate, P., Mogre, S., Diers, A. R., … Sarangarajan, R. (2018). BPM 31510, a clinical stage metabolic modulator, demonstrates therapeutic efficacy in glioblastoma models of temozolomide chemosensitive and resistance by targeting mitochondrial function. CANCER RESEARCH, 78(13). -
Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases
Koenig, J. L., Shi, S., Sborov, K., Gensheimer, M. F., Le, G., Nagpal, S., … Pollom, E. L. (2019). Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases. WORLD NEUROSURGERY, 126, E1399–E1411. -
Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2019). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. ONCOLOGIST, 24(6), 836–43. -
To Biopsy or Not to Biopsy? A case of primary intramedullary spinal cord lymphoma presenting as longitudinally extensive transverse myelitis within cervical cord
Satyanarayan, S., Rizvi, A., & Nagpal, S. (2019). To Biopsy or Not to Biopsy? A case of primary intramedullary spinal cord lymphoma presenting as longitudinally extensive transverse myelitis within cervical cord. NEUROLOGY, 92(15). -
Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.
Thomas, R. P., Nagpal, S., Iv, M., Soltys, S. G., Bertrand, S., Pelpola, J. S., … Recht, L. (2019). Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Nodular Leptomeningeal Disease - A Distinct Pattern of Recurrence After Post-Resection Stereotactic Radiosurgery for Brain Metastases: A Multi-Institutional Study of Inter-Observer Reliability.
Turner, B. E., Prabhu, R. S., Burri, S. H., Brown, P. D., Pollom, E. L., Milano, M. T., … Soltys, S. G. (2019). Nodular Leptomeningeal Disease - A Distinct Pattern of Recurrence After Post-Resection Stereotactic Radiosurgery for Brain Metastases: A Multi-Institutional Study of Inter-Observer Reliability. International Journal of Radiation Oncology, Biology, Physics. -
BPM31510 exploits differential redox vulnerabilities between normal and glioblastoma cells to mediate its anti-cancer effect
Sun, J., Nagpal, S., Patel, C., Merchant, M., Jang, T., Diers, A. R., … Recht, L. (2019). BPM31510 exploits differential redox vulnerabilities between normal and glioblastoma cells to mediate its anti-cancer effect. CANCER RESEARCH, 79(13). -
Macrophage exclusion after radiation therapy (MERT): A new and effective way to increase the therapeutic ratio of radiotherapy.
Brown, J. M., Thomas, R., Nagpal, S., & Recht, L. (2019). Macrophage exclusion after radiation therapy (MERT): A new and effective way to increase the therapeutic ratio of radiotherapy. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 144, 159–64. -
Professor Seema Nagpal: which one should be given the priority, radiation or drug?
Zhou, M., Zhou, A., & Nagpal, S. (2019). Professor Seema Nagpal: which one should be given the priority, radiation or drug? ANNALS OF TRANSLATIONAL MEDICINE, 7(22). -
A Phase I/II Trial of 5-Fraction Stereotactic Radiosurgery with 5-mm Margins with Concurrent Temozolomide in Newly Diagnosed Glioblastoma: Primary Outcomes.
Azoulay, M., Chang, S. D., Gibbs, I. C., Hancock, S. L., Pollom, E. L., Harsh, G. R., … Soltys, S. G. (2020). A Phase I/II Trial of 5-Fraction Stereotactic Radiosurgery with 5-mm Margins with Concurrent Temozolomide in Newly Diagnosed Glioblastoma: Primary Outcomes. Neuro-Oncology. -
EVALUATION OF [18F]DASA-23 FOR NON-INVASIVE MEASUREMENT OF ABERRANTLY EXPRESSED PYRUVATE KINASE M2 IN GLIOMA: FIRST-IN-HUMAN STUDY
Patel, C., Beinat, C., Haywood, T., Murty, S., Xie, Y., Recht, L., … Gambhir, S. (2019). EVALUATION OF [18F]DASA-23 FOR NON-INVASIVE MEASUREMENT OF ABERRANTLY EXPRESSED PYRUVATE KINASE M2 IN GLIOMA: FIRST-IN-HUMAN STUDY. NEURO-ONCOLOGY, 21, 169. -
A PHASE 1 STUDY OF BPM31510 PLUS VITAMIN K IN SUBJECTS WITH HIGH-GRADE GLIOMA THAT HAS RECURRED ON A BEVACIZUMAB-CONTAINING REGIMEN
Recht, L., Thomas, R., Bertrand, S., Yerballa, P., Li, G., Iv, M., … Nagpal, S. (2019). A PHASE 1 STUDY OF BPM31510 PLUS VITAMIN K IN SUBJECTS WITH HIGH-GRADE GLIOMA THAT HAS RECURRED ON A BEVACIZUMAB-CONTAINING REGIMEN. NEURO-ONCOLOGY, 21, 27. -
EVALUATION OF DYNAMIN 2 (DNM2) AS A THERAPEUTIC TARGET IN LEPTOMENINGEAL METASTATIC DISEASE
Chernikova, S., Polyak, D., Deng, J., Tsau, S., Casey, K., Johnson, E., … Gephart, M. H. (2019). EVALUATION OF DYNAMIN 2 (DNM2) AS A THERAPEUTIC TARGET IN LEPTOMENINGEAL METASTATIC DISEASE. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
COMPREHENSIVE RNA ANALYSIS OF CEREBROSPINAL FLUID FROM LEPTOMENINGEAL METASTASES
Polyak, D., Li, Y., Liu, B., Connolly, I., Khoeur, L., Kakusa, B. W., … Gephart, M. H. (2019). COMPREHENSIVE RNA ANALYSIS OF CEREBROSPINAL FLUID FROM LEPTOMENINGEAL METASTASES. NEURO-ONCOLOGY, 21, 62. -
TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
Cloughesy, T., Petrecca, K., Walbert, T., Butowski, N., Salacz, M., Perry, J., … Vogelbaum, M. (2019). TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA. NEURO-ONCOLOGY, 21, 284. -
Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma.
Jin, M. C., Liu, E. K., Shi, S., Gibbs, I. C., Thomas, R., Recht, L., … Li, G. (2020). Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma. Frontiers in Oncology, 10, 337. -
AN OPEN-LABEL, MULTI-CENTER TRIAL OF INO-5401 AND INO-9012 DELIVERED BY ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB IN SUBJECTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA (GBM)
Skolnik, J., Reardon, D., Brem, S., Desai, A., Bagley, S., Kurz, S., … Boyer, J. (2020). AN OPEN-LABEL, MULTI-CENTER TRIAL OF INO-5401 AND INO-9012 DELIVERED BY ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB IN SUBJECTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA (GBM). JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8, A8. -
Executive Summary from American Radium Society's Appropriate Use Criteria on Neurocognition after stereotactic radiosurgery for multiple brain metastases.
Milano, M. T., Chiang, V. L., Soltys, S. G., Wang, T. J., Lo, S. S., Brackett, A., … Chang, E. L. (2020). Executive Summary from American Radium Society's Appropriate Use Criteria on Neurocognition after stereotactic radiosurgery for multiple brain metastases. Neuro-Oncology. -
High levels of ubidecarenone (oxidized CoQ10) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells.
Sun, J., Patel, C. B., Jang, T., Merchant, M., Chen, C., Kazerounian, S., … Recht, L. (2020). High levels of ubidecarenone (oxidized CoQ10) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells. Scientific Reports, 10(1), 13899. -
Rapid Fluctuation of Subretinal Fluid on Encorafenib and Binimetinib.
Li, A. S., Leng, T., Nagpal, S., & Liao, Y. J. (2020). Rapid Fluctuation of Subretinal Fluid on Encorafenib and Binimetinib. Retina (Philadelphia, Pa.). -
Stereotactic Radiosurgery After Resection of Brain Metastases: Changing Patterns of Care in the United States.
Chin, A. L., Li, G., Gephart, M. H., Sandhu, N., Nagpal, S., Soltys, S. G., & Pollom, E. L. (2020). Stereotactic Radiosurgery After Resection of Brain Metastases: Changing Patterns of Care in the United States. World Neurosurgery. -
Phase I study of BPM31510 and vitamin K in patients with high grade glioma recurrent after a bevacizumab-containing regimen.
Nagpal, S., Thomas, R. P., Bertrand, S., Yerraballa, H. P., Iv, M., Li, G., … Recht, L. D. (2020). Phase I study of BPM31510 and vitamin K in patients with high grade glioma recurrent after a bevacizumab-containing regimen. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results.
Reardon, D. A., Brem, S., Desai, A. S., Bagley, S. J., Kurz, S. C., De La Fuente, M. I., … Skolnik, J. (2020). INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis.
Li, X., Sigworth, E. A., Wu, A. H., Behrens, J., Etemad, S. A., Nagpal, S., … Warner, J. L. (2020). Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis. Scientific Reports, 10(1), 17536. -
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., … Darlow, S. D. (2020). Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(11), 1537–70. -
SECOND GENERATION BRAF/MEK INHIBITION IN ANAPLASTIC PLEOMORPHIC XANTHROASTROCYTOMA
Stocksdale, B., Liao, Y. J., Coffey, G., & Nagpal, S. (2020). SECOND GENERATION BRAF/MEK INHIBITION IN ANAPLASTIC PLEOMORPHIC XANTHROASTROCYTOMA. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
Neuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma.
Stocksdale, B., Nagpal, S., Hixson, J. D., Johnson, D. R., Rai, P., Shivaprasad, A., & Tremont-Lukats, I. W. (2020). Neuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma. Neuro-Oncology Practice, 7(6), 583–88. -
Report from the American Radium Society (ARS) Appropriate Use Criteria Brain Malignancies Panel: Treatment of Multiple Brain Metastases
Milano, M., Chiang, V., Soltys, S., Wang, T., Lo, S., Brackett, A., … Chang, E. (2020). Report from the American Radium Society (ARS) Appropriate Use Criteria Brain Malignancies Panel: Treatment of Multiple Brain Metastases. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
BPM31510, a Coenzyme Q10 (CoQ10) containing lipid nanodispersion, enhances radiation effects to prolong survival in a rodent glioblastoma model
Sun, J., Merchant, M., Diers, A. R., Kazerounian, S., Gesta, S., Narain, N. R., … Recht, L. (2020). BPM31510, a Coenzyme Q10 (CoQ10) containing lipid nanodispersion, enhances radiation effects to prolong survival in a rodent glioblastoma model. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
Su, C. C., Wu, J. T., Neal, J. W., Popat, R. A., Kurian, A. W., Backhus, L. M., … Han, S. S. (2021). Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial.
Zhou, Q., van den Berg, N. S., Rosenthal, E. L., Iv, M., Zhang, M., Vega Leonel, J. C., … Li, G. (2021). EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial. Theranostics, 11(15), 7130–7143. -
Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.
Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., … McCoach, C. E. (2021). Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
EF-32 (TRIDENT): A pivotal randomized trial of radiation therapy concomitant with temozolomide plus /- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma.
Shi, W., Kleinberg, L., Jeyapalan, S. A., Goldlust, S. A., Nagpal, S., Combs, S. E., … Glas, M. (2021). EF-32 (TRIDENT): A pivotal randomized trial of radiation therapy concomitant with temozolomide plus /- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma.
Beinat, C., Patel, C. B., Haywood, T., Murty, S., Naya, L., Castillo, J. B., … Gambhir, S. S. (2021). A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
American Radium Society Appropriate Use Criteria for the Management of Brain Metastases in EGFR-mutated Non-Small Cell Lung Cancer
Nagpal, S., Chiang, V., Milano, M., Soltys, S., Ahluwalia, M., Chao, S., … Chang, E. (2021). American Radium Society Appropriate Use Criteria for the Management of Brain Metastases in EGFR-mutated Non-Small Cell Lung Cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
American Radium Society's Appropriate Use Criteria on Postoperative Management of Lower Grade Gliomas
Tom, M., Milano, M., Soltys, S., Sahgal, A., Knisely, J., Chiang, V., … Chang, E. (2021). American Radium Society's Appropriate Use Criteria on Postoperative Management of Lower Grade Gliomas. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases.
Li, Y., Polyak, D., Lamsam, L., Connolly, I. D., Johnson, E., Khoeur, L. K., … Hayden Gephart, M. (2021). Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases. NPJ Precision Oncology, 5(1), 90. -
Management of complications from brain metastasis treatment: a narrative review.
Diao, K., Sosa, A. J., Zada, G., Nagpal, S., & Chang, E. L. (2021). Management of complications from brain metastasis treatment: a narrative review. Chinese Clinical Oncology. -
Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM 31510-IV treatment in advanced glioblastoma multiforme patients.
Nagpal, S., Sarangarajan, R., Bruce, C., Miller, G. M., Rodrigues, L. O., Shah, P., … Recht, L. D. (2021). Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM 31510-IV treatment in advanced glioblastoma multiforme patients. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
A Case of Isolated Leptomeningeal Progression in a Patient with NTRK Fusion plus Uterine Sarcoma
Lanman, T., Hayden, M., Bui, N., & Nagpal, S. (2021). A Case of Isolated Leptomeningeal Progression in a Patient with NTRK Fusion plus Uterine Sarcoma. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"
Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., … McCoach, C. E. (1800). In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?". Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 17(2), e12–e14. -
Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.
Lanman, T., Hayden Gephart, M., Bui, N., Toland, A., & Nagpal, S. (2021). Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report. Case Reports in Oncology, 14(3), 1841–1846. -
18F-FSPG PET/CT Imaging of System xC- Transporter Activity in Patients with Primary and Metastatic Brain Tumors.
Wardak, M., Sonni, I., Fan, A. P., Minamimoto, R., Jamali, M., Hatami, N., … Mittra, E. S. (2022). 18F-FSPG PET/CT Imaging of System xC- Transporter Activity in Patients with Primary and Metastatic Brain Tumors. Radiology, 203296. -
Executive summary of american radium society's appropriate use criteria for the postoperative management of lower grade gliomas.
Tom, M. C., Milano, M. T., Chao, S. T., Soltys, S. G., Knisely, J. P., Sahgal, A., … Chang, E. L. (2022). Executive summary of american radium society's appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. -
Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.
Gondi, V., Bauman, G., Bradfield, L., Burri, S. H., Cabrera, A. R., Cunningham, D. A., … Brown, P. D. (2022). Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology. -
Preclinical Modeling in Leptomeningeal Disease: Starting at the foundation to tackle a difficult disease.
Kumthekar, P., & Nagpal, S. (2022). Preclinical Modeling in Leptomeningeal Disease: Starting at the foundation to tackle a difficult disease. Neuro-Oncology. -
Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes.
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., … Han, S. S. (2022). Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes. JCO Precision Oncology, 6, e2200220. -
Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
Hui, C., Qu, V., Wang, J.-Y. Y., von Eyben, R., Chang, Y.-C. C., Chiang, P.-L. L., … Pollom, E. (2022). Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. Journal of Neuro-Oncology. -
Intramuscular (IM) INO-5401+INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.
Reardon, D. A., Brem, S., Desai, A. S., Bagley, S. J., Kurz, S. C., De La Fuente, M. I., … Skolnik, J. (2022). Intramuscular (IM) INO-5401+INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
ANIMAL STUDIES WITH A NEW CNS DRUG DELIVERY DEVICE TO EFFECTIVELY TREAT LEPTOMENINGEAL CARCINOMATOSIS PATIENTS
Kumthekar, P., Benatti, H., Taghian, T., Gormley, W. B., Nagpal, S., Baker, W. C., … Gray-Edwards, H. (2022). ANIMAL STUDIES WITH A NEW CNS DRUG DELIVERY DEVICE TO EFFECTIVELY TREAT LEPTOMENINGEAL CARCINOMATOSIS PATIENTS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
A MULTI-INSTITUTIONAL RETROSPECTIVE SERIES OF ADULT-ONSET MEDULLOBLASTOMA.
Bonm, A., Rutenberg, M., Therkelsen, K., Ruiz, A., McGranahan, T., Cimino, P., … Taylor, L. (2022). A MULTI-INSTITUTIONAL RETROSPECTIVE SERIES OF ADULT-ONSET MEDULLOBLASTOMA. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
A SINGLE-INSTITUTION RETROSPECTIVE SERIES OF SARS-COV-2 INFECTION IN ADULT GLIOMA PATIENTS
Lanman, T., Ruiz, A., & Nagpal, S. (2022). A SINGLE-INSTITUTION RETROSPECTIVE SERIES OF SARS-COV-2 INFECTION IN ADULT GLIOMA PATIENTS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
NCCN Guidelines Insights: Central Nervous System Cancers, Version 2.2022.
Horbinski, C., Nabors, L. B., Portnow, J., Baehring, J., Bhatia, A., Bloch, O., … Darlow, S. (2023). NCCN Guidelines Insights: Central Nervous System Cancers, Version 2.2022. Journal of the National Comprehensive Cancer Network : JNCCN, 21(1), 12–20. -
Patterns of Progression in Patients with Newly Diagnosed Glioblastoma Treated with 5 mm Margins on a Phase I/II Trial of 5 Fraction Stereotactic Radiosurgery with Concurrent and Adjuvant Temozolomide.
Mendoza, M. G., Azoulay, M., Chang, S. D., Gibbs, I. C., Hancock, S. L., Pollom, E. L., … Soltys, S. G. (2023). Patterns of Progression in Patients with Newly Diagnosed Glioblastoma Treated with 5 mm Margins on a Phase I/II Trial of 5 Fraction Stereotactic Radiosurgery with Concurrent and Adjuvant Temozolomide. Practical Radiation Oncology. -
Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Hui, C., Qu, V., Wang, J. Y., Von Eyben, R., Chang, Y. C., Chiang, P. L., … Pollom, E. (2022). Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.
Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., … Nagpal, S. (2023). Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging. Frontiers in Oncology, 13, 1139940. -
Diagnostic and Therapeutic Updates in Leptomeningeal Disease.
Roy-O'Reilly, M. A., Lanman, T., Ruiz, A., Rogawski, D., Stocksdale, B., & Nagpal, S. (2023). Diagnostic and Therapeutic Updates in Leptomeningeal Disease. Current Oncology Reports. -
A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors.
Piha-Paul, S. A., Nagpal, S., Weise, A. M., Braiteh, F. S., Chen, C., Huang, C. Q., … Tsai, K. K. (2023). A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma
Shi, W., Roberge, D., Kleinberg, L., Jeyapalan, S. A., Goldlust, S. A., Nagpal, S., … Glas, M. (2023). Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Parental Leave Experience for Academic Neurology Faculty at 19 Academic Centers
He, A., Grewal, P., Rodrigues, K., Shah, S., Alexander, H., Yang, A., … Alick-Lindstrom, S. (2023). Parental Leave Experience for Academic Neurology Faculty at 19 Academic Centers. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of Gender and Race on Academic Achievements for Neurology Faculty
Patel, S., Grewal, P., Nobleza, C. O., Ayub, N., Kung, D., Shah, S., … Allendorfer, J. (2023). Impact of Gender and Race on Academic Achievements for Neurology Faculty. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
A Single-Institution Retrospective Series of SARS-CoV-2 Infection in Adult Glioma Patients.
Lanman, T., Ruiz, A. N., & Nagpal, S. (2023). A Single-Institution Retrospective Series of SARS-CoV-2 Infection in Adult Glioma Patients. Case Reports in Oncology, 16(1), 980–987. -
Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma.
Iv, M., Naya, L., Sanan, S., Van Buskirk, S. L., Nagpal, S., Thomas, R. P., … Patel, C. B. (2023). Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma. The Neuroradiology Journal, 19714009231207083. -
High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers
Ma, J., Chen, K., Ding, Y., Li, X., Tang, Q., Jin, B., … Chen, B. (2023). High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers. FRONTIERS IN MOLECULAR BIOSCIENCES, 10. -
High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers.
Ma, J., Chen, K., Ding, Y., Li, X., Tang, Q., Jin, B., … Chen, B. (2023). High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers. Frontiers in Molecular Biosciences, 10, 1257079. -
Impact of language barriers and use of interpreters on hope among patients with Central Nervous System Malignancies and Bone Metastases.
Hui, C., Hall, J., Fang, Z., Lefebvre, S., Hayden-Gephart, M., Li, G., … Pollom, E. (2023). Impact of language barriers and use of interpreters on hope among patients with Central Nervous System Malignancies and Bone Metastases. International Journal of Radiation Oncology, Biology, Physics. -
Ready to INDIGO: Vorasidenib Ushers in the Era of Isocitrate Dehydrogenase Inhibition in Low-Grade Glioma.
Lanman, T. A., Cao, T. Q., Miller, J. J., & Nagpal, S. (2024). Ready to INDIGO: Vorasidenib Ushers in the Era of Isocitrate Dehydrogenase Inhibition in Low-Grade Glioma. International Journal of Radiation Oncology, Biology, Physics, 118(2), 334–336. -
A rare non-gadolinium enhancing sarcoma brain metastasis with microenvironment dominated by tumor-associated macrophages.
Rogawski, D., Wheeler, J., Nie, E., Zhu, W., Villanueva, E., Coffey, G., … Nagpal, S. (2024). A rare non-gadolinium enhancing sarcoma brain metastasis with microenvironment dominated by tumor-associated macrophages. Acta Neuropathologica Communications, 12(1), 15. -
INTERNAL CAROTID INJECTION MODEL OF BRAIN METASTASIS DESCRIBES LEPTOMENINGEAL DISEASE
Chernikova, S., Tsau, S., Wang, Y., Hartmann, G., Polyak, D., Bhambhvani, H., … Gephart, M. H. (2023). INTERNAL CAROTID INJECTION MODEL OF BRAIN METASTASIS DESCRIBES LEPTOMENINGEAL DISEASE. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
A LONGITUDINAL THERAPY RESPONSE MONITORING STUDY IN SUBJECTS WITH LEPTOMENINGEAL METASTASES USING CNSIDE COMPARED TO STANDARD OF CARE (CSF CYTOLOGY, CLINICAL EVALUATION, IMAGING)
Nagpal, S., Youssef, M., Beruti, S., Gillis, L., Gordon, K., Blouw, B., & Kumthekar, P. (2023). A LONGITUDINAL THERAPY RESPONSE MONITORING STUDY IN SUBJECTS WITH LEPTOMENINGEAL METASTASES USING CNSIDE COMPARED TO STANDARD OF CARE (CSF CYTOLOGY, CLINICAL EVALUATION, IMAGING). NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
TRIAL IN PROGRESS: A PHASE 2 STUDY OF BPM 31510 (AN OXIDIZED COQ10-LIPID CONJUGATE NANODISPERSION) WITH VITAMIN K AND STANDARD CHEMORADIATION IN NEWLY DIAGNOSED GLIOBLASTOMA
Stocksdale, B., Bertrand, S., Villanueva, E., Naya, L., Molaie, D., Lyng, A., … Nagpal, S. (2023). TRIAL IN PROGRESS: A PHASE 2 STUDY OF BPM 31510 (AN OXIDIZED COQ10-LIPID CONJUGATE NANODISPERSION) WITH VITAMIN K AND STANDARD CHEMORADIATION IN NEWLY DIAGNOSED GLIOBLASTOMA. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
A RANDOMIZED WINDOW OF OPPORTUNITY TRIAL WITH DOSE ESCALATION TO EVALUATE FLUOXETINE AND TEMOZOLOMIDE IN GLIOMA
Singh, K., Railton, C., Hotchkiss, K., Herndon, J., Peters, K., Friedman, H., … Khasraw, M. (2023). A RANDOMIZED WINDOW OF OPPORTUNITY TRIAL WITH DOSE ESCALATION TO EVALUATE FLUOXETINE AND TEMOZOLOMIDE IN GLIOMA. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
THE PIVOTAL TRIDENT STUDY OF TUMOR TREATING FIELDS (TTFIELDS) THERAPY WITH CHEMORADIATION, FOLLOWED BY MAINTENANCE TTFIELDS THERAPY/TEMOZOLOMIDE (TMZ), IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM)
Shi, W., Glas, M., Roberge, D., Kleinberg, L., Jeyapalan, S., Goldlust, S., … Grossman, R. (2023). THE PIVOTAL TRIDENT STUDY OF TUMOR TREATING FIELDS (TTFIELDS) THERAPY WITH CHEMORADIATION, FOLLOWED BY MAINTENANCE TTFIELDS THERAPY/TEMOZOLOMIDE (TMZ), IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM). NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
STANDARD WORK FOR ORAL CHEMOTHERAPY IMPROVES SAFETY WITHOUT INCREASING DELAYS
Balakrishnan, S., Nagpal, S., Dugala, A., Coffey, G., & Pena, J. (2023). STANDARD WORK FOR ORAL CHEMOTHERAPY IMPROVES SAFETY WITHOUT INCREASING DELAYS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
Global metabolomics revealed deviations from the metabolic aging clock in colorectal cancer patients.
Zhang, L., Mo, S., Zhu, X., Chou, C. J., Jin, B., Han, Z., … Peng, J. (2024). Global metabolomics revealed deviations from the metabolic aging clock in colorectal cancer patients. Theranostics, 14(4), 1602–1614. -
Executive Summary of the American Radium Society Appropriate Use Criteria for Brain Metastases in EGFR-mutated and ALK-fusion Non-Small Cell Lung Cancer.
Nagpal, S., Milano, M. T., Chiang, V. L., Soltys, S. G., Brackett, A., Halasz, L. M., … Chang, E. L. (2024). Executive Summary of the American Radium Society Appropriate Use Criteria for Brain Metastases in EGFR-mutated and ALK-fusion Non-Small Cell Lung Cancer. Neuro-Oncology. -
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.
Azad, T. D., Nanjo, S., Jin, M. C., Chabon, J. J., Kurtz, D. M., Chaudhuri, A. A., … Diehn, M. (2024). Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis. NPJ Precision Oncology, 8(1), 121. -
The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy.
Kumthekar, P. U., Blouw, B., Corkos, P., Nagpal, S., Tripathy, A., Piccioni, D., & Youssef, M. (2024). The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy. Frontiers in Oncology, 14, 1402651. -
Leptomeningeal metastases from solid tumors: A SNO and ASCO consensus review on clinical management and future directions.
Wilcox, J. A., Chukwueke, U. N., Ahn, M.-J. J., Aizer, A. A., Bale, T. A., Brandsma, D., … Boire, A. A. (2024). Leptomeningeal metastases from solid tumors: A SNO and ASCO consensus review on clinical management and future directions. Neuro-Oncology. -
Morvan Fibrillary Chorea Associated with Monoclonal B Cell Lymphocytosis.
Park, D., Means, J., Campion, A. W., Kelton, A., Nagpal, S., & Abdulhaq, H. (2024). Morvan Fibrillary Chorea Associated with Monoclonal B Cell Lymphocytosis. The American Journal of Case Reports, 25, e943867. -
Analysis of Faculty Gender and Race in Scholarly Achievements in Academic Neurology.
Patel, S. I., Grewal, P., Nobleza, C. O. H., Ayub, N., Ky, K.-E. E., Kung, D. H., … Allendorfer, J. B. (2024). Analysis of Faculty Gender and Race in Scholarly Achievements in Academic Neurology. Journal of Women's Health (2002). -
Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.
Rogawski, D., Cao, T., Ma, Q., Roy-O'Reilly, M., Yao, L., Xu, N., & Nagpal, S. (2024). Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression. Journal of Neuro-Oncology. -
Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors.
Ma, J., Lin, Z., Zhang, Y., Ding, Y., Tang, Q., Qian, Y., … Chen, B. (2024). Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors. Frontiers in Immunology, 15, 1343109. -
A phase II study of plerixafor combined with whole brain radiation therapy (WBRT) for patients with newly diagnosed glioblastoma
Cao, T., Gu, Y., Yagmurlu, B., Yerraballa, H. P., Bertrand, S., Naya, L., … Recht, L. D. (2024). A phase II study of plerixafor combined with whole brain radiation therapy (WBRT) for patients with newly diagnosed glioblastoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with <i>BRAF V600</i>-mutated solid tumors
Piha-Paul, S. A., De La Fuente, M. I., Iwamoto, F., Nagpal, S., Weise, A. M., Zhu, J.-J., … Tsai, K. K. (2024). Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Novel non-invasive method for measuring intracranial pressure for drug delivery and other neurologic disorders.
Kumthekar, P., Schwartz, M., Nagpal, S., Glitza, I. C., Forsyth, P. A. J., Gormley, W., … Sonabend, A. M. (2024). Novel non-invasive method for measuring intracranial pressure for drug delivery and other neurologic disorders. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023
Warner, J. L., Bakow, B. R., Brown, A. J., Choe, J. H., Fan, E., Ganta, T., … Rubinstein, S. (2024). Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Evaluation of the study of control arms in randomized clinical trials of cancer.
Jain, S. K., Zauderer, M. G., Sethi, T., Schoen, M. W., Rubinstein, S., Nguyen, R. H.-T., … Warner, J. L. (2024). Evaluation of the study of control arms in randomized clinical trials of cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Perceptions of Lactation Experience Among Neurology Faculty and Impact of Lactation Time on Academic Achievement at U.S. Academic Medical Centers.
Durica, S. R., Miller, J., Zheng, C., Grewal, P., Zhao, C., Alexander, H. B., … Patel, S. I. (2024). Perceptions of Lactation Experience Among Neurology Faculty and Impact of Lactation Time on Academic Achievement at U.S. Academic Medical Centers. Journal of Women's Health (2002).
-
Treatment and Prevention of Secondary CNS Lymphoma
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
- Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
- A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
- A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
- Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
- Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
- A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Practice Locations
Stanford Neuroscience Health Center Palo Alto, CA
Palo Alto, CAStanford Neuroscience Health Center
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereBrain and Spine Tumor Center at Stanford Cancer Center Palo Alto, CA
Palo Alto, CABrain and Spine Tumor Center at Stanford Cancer Center
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereNeurogenetic Cancer Palo Alto, CA
Palo Alto, CANeurogenetic Cancer
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(114 reviews)
View More
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records